A detailed history of Israel Englander (Millennium Management LLC) transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 1,158,508 shares of CTXR stock, worth $3.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,158,508
Previous 2,048,860 43.46%
Holding current value
$3.63 Million
Previous $1.19 Million 51.26%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.48 - $1.02 $427,368 - $908,159
-890,352 Reduced 43.46%
1,158,508 $579,000
Q2 2024

Aug 14, 2024

BUY
$0.58 - $1.03 $1.19 Million - $2.11 Million
2,048,860 New
2,048,860 $1.19 Million
Q2 2023

Aug 14, 2023

SELL
$1.08 - $1.65 $261,151 - $398,981
-241,807 Reduced 79.42%
62,675 $75,000
Q1 2023

May 15, 2023

SELL
$0.78 - $1.42 $192,382 - $350,234
-246,644 Reduced 44.75%
304,482 $356,000
Q4 2022

Feb 14, 2023

SELL
$0.79 - $1.28 $184,586 - $299,077
-233,654 Reduced 29.77%
551,126 $435,000
Q3 2022

Nov 14, 2022

SELL
$0.14 - $1.33 $133,761 - $1.27 Million
-955,440 Reduced 54.9%
784,780 $950,000
Q2 2022

Aug 15, 2022

BUY
$0.88 - $1.87 $1.53 Million - $3.25 Million
1,740,220 New
1,740,220 $1.6 Million
Q2 2021

Aug 16, 2021

SELL
$1.51 - $4.23 $253,873 - $711,181
-168,128 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$1.04 - $2.34 $164,404 - $369,909
158,081 Added 1573.41%
168,128 $299,000
Q4 2020

Feb 16, 2021

BUY
$0.9 - $1.2 $9,042 - $12,056
10,047 New
10,047 $10,000
Q4 2017

Feb 14, 2018

SELL
$2.65 - $5.1 $52,954 - $101,913
-19,983 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$2.69 - $4.03 $53,754 - $80,531
19,983
19,983 $63,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $457M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.